66th ASH Annual Meeting

Preview Day on the Virtual Platform

Events

Preview Day on the Virtual Platform

Events

Registration at the Airport (for in-person participants)

Events

Registration at the Convention Center (for in-person participants)

Events

Registration at the Airport (for in-person participants)

Events

Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia – What Clinicians Want to Know

Friday Satellite Symposia

Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia - What Clinicians Want to Know

Friday Satellite Symposia

Advances in Paroxysmal Nocturnal Hemoglobinuria: Reshaping Management Decision-Making through Case Challenges Together with the International PNH Interest Group

Friday Satellite Symposia

An Interactive Case-based Review of Chronic Lymphocytic Leukemia: Experts Explore the Latest Evidence and Guideline Updates

Friday Satellite Symposia

Bridging Gaps in Multiple Myeloma Care: A Community Oncologist's Guide to Navigating the Evolving Treatment Landscape

Friday Satellite Symposia

Championing the Care of Relapsed/Refractory Multiple Myeloma: Practical Strategies to Integrate Bispecific Antibodies

Friday Satellite Symposia

Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience + Innovation for More Personalized Disease Control

Friday Satellite Symposia

MDS 2024: Let’s Overcome the Challenges

Friday Satellite Symposia

Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease

Friday Satellite Symposia

Learn, Engage, and Relax in ASH Central (for in-person participants)

Events

Registration at the Convention Center (for in-person participants)

Events

Registration at the Grand Hyatt (for in-person participants)

Events

Registration at the Marriott Marquis (for in-person participants)

Events

Training Program Directors Workshop

Special-Interest Sessions

Addressing Current Questions and Controversies in the Management of Myelofibrosis - What Clinicians Want to Know

Friday Satellite Symposia

Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma - What Clinicians Want to Know

Friday Satellite Symposia

Advances in the Management of Myeloproliferative Neoplasms and Systemic Mastocytosis: Diagnosis/Classification, Risk Stratification, and Optimal Therapeutic Selection

Friday Satellite Symposia

A Game Changer for Follicular Lymphoma: Mastering Use of Precision Therapies as Part of a Chemo-free Treatment Paradigm

Friday Satellite Symposia

A New Era for Hemophilia Treatment: Common Goals, Unique Perspectives

Friday Satellite Symposia

Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors

Friday Satellite Symposia

A Violent Graft in a Vulnerable Host: The Future of aGVHD Management

Friday Satellite Symposia

Collaborating for Optimal Immune Thrombocytopenia Care: Uniting Disease, Treatment, and Patient-Centered Considerations

Friday Satellite Symposia

Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-base Platforms

Friday Satellite Symposia

Emerging insights in biology and treatment approaches to Peripheral T cell Lymphomas

Friday Satellite Symposia

Escape the Amyloid Maze: Unraveling Data and Care Strategies for AL Amyloidosis

Friday Satellite Symposia

Evolving Treatment Paradigms for Patients with Hemoglobinopathies

Friday Satellite Symposia

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Friday Satellite Symposia

Guiding Our Patient's Path: Managing First Relapse in Diffuse Large B-Cell Lymphoma Outside of CAR Ts

Friday Satellite Symposia

Maximizing Touchpoints to Empower Impactful Patient-Centered Care for Paroxysmal Nocturnal Hemoglobinuria

Friday Satellite Symposia

Medical Crossfire®: Bridging Evidence to Practice in AML... Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Friday Satellite Symposia

Next Up: Conversations On Optimizing CD38 Antibody-Based Triplet Regimens For Early-Relapse Multiple Myeloma

Friday Satellite Symposia

Treatment Crossroads: Diverse Perspectives on Treatment Strategies for Relapsed/Refractory DLBCL and FL

Friday Satellite Symposia

Scientific Workshop on Aging and Hematology

Scientific Workshops

Scientific Workshop on Challenges and Novel Technologies in Red Blood Cell Quality Assessment

Scientific Workshops

Scientific Workshop on Clonal Hematopoiesis

Scientific Workshops

Scientific Workshop on Decentralized Clinical Trials in Hematology: Reshaping the Traditional Clinical Trial Paradigm With AI Strategies for 'Real World' Patient Representation

Scientific Workshops

Scientific Workshop on Genomic Toxicities of Gene and Cell Therapies

Scientific Workshops

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

Scientific Workshops

Scientific Workshop on Interplay Between Coagulation and Malignancy

Scientific Workshops

Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Discovery to Patients

Scientific Workshops

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies

Scientific Workshops

Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies

Scientific Workshops

Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia - What Clinicians Want to Know

Friday Satellite Symposia

Addressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know

Friday Satellite Symposia

A Step-By-Step Approach to CAR T-cell Therapy for RRMM: From Bridging to Sequencing and Adverse Event Management

Friday Satellite Symposia

Bispecific Antibodies: A Playbook for Relapsed/Refractory Follicular Lymphoma

Friday Satellite Symposia

Broadening the Impact of Whole-Genome and Transcriptome Sequencing (WG(T)S) in Hematological Malignancies

Friday Satellite Symposia

Cases and Conversations™: The Rationale for Utilizing Non-Factor Replacement Therapies in Hemophilia Care

Friday Satellite Symposia

Clinical assessment of gene therapies for hemophilia A and hemophilia B: Key takeaways for your practice

Friday Satellite Symposia

Collaboration In Chronic ITP: Improving Quality Of Life And Patient Outcomes

Friday Satellite Symposia

Complex Cases in the Community Clinic: Managing Diverse Hematologic Malignancies

Friday Satellite Symposia

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

Friday Satellite Symposia

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Friday Satellite Symposia

Sharing Best Practices from the ALL/LBL Clinic: Navigating Patient-Centered Care with Asparaginase Therapies

Friday Satellite Symposia

Unleashing Emerging Therapies to Modify Myelofibrosis Pathogenesis: Shifting the Treatment Paradigm to Target Deeper Clinical and Molecular Responses

Friday Satellite Symposia

Accelerating the Adoption of the Latest Evidence on Sequencing Therapies for Multiple Myeloma Across Practice Settings

Friday Satellite Symposia

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

Friday Satellite Symposia

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Friday Satellite Symposia

Show Me the Data™: Pushing CAR T’s Forward Across Lymphoid Malignancies... Accelerating Access in the Community and Treatment Strategies for the Road Ahead

Friday Satellite Symposia

ASH Yoga (for in-person participants)

Events

Learn, Engage, and Relax in ASH Central (for in-person participants)

Events

Registration at the Convention Center (for in-person participants)

Events

Registration at the Grand Hyatt (for in-person participants)

Events

Registration at the Marriott Marquis (for in-person participants)

Events

Coffee and Collaboration in ASH Central (for in-person participants)

Events

How I Treat: Acute Lymphoblastic Leukemia Incorporating New Treatment Options (ticketed session for in-person participants)

How I Treat

How I Treat: Challenges and Management of Cancer Associated Thrombosis (ticketed session for in-person participants)

How I Treat

How I Treat: Follicular Lymphoma Incorporating New Treatment Options (ticketed session for in-person participants)

How I Treat

How I Treat: Gene Therapy in Sickle Cell Disease (ticketed session for in-person participants)

How I Treat

How I Treat: Options for Long-Term Management of Hemophilia (ticketed session for in-person participants)

How I Treat

Meet the Scientist: CAR-T and CAR-NK in Therapy of Hematologic Malignancies (Ticketed session for in-person participants)

Meet the Scientist

Meet the Scientist: Epigenetic Regulation in Bone Marrow Failure (Ticketed session for in-person participants)

Meet the Scientist

Meet the Scientist: Production of Functional Hematopoietic Stem Cells from Pluripotent Cells (Ticketed session for in-person participants)

Meet the Scientist

Meet the Scientist: Therapy-Related Myeloid Neoplasms (Ticketed session for in-person participants)

Meet the Scientist

Meet the Scientist: Transferrin Receptor Physiology and Iron Metabolism (Ticketed session for in-person participants)

Meet the Scientist

Nonmalignant Hematologic Disorders Forum: Deeper Dive Into PNH, aHUS, and ITP

Industry Forums

Advocating for Language Justice in Hematology

Health Equity Studio

Coffee Break in the Poster Hall (for in-person participants)

Events

Meet the Blood Vessels, Thrombosis & Hemostasis Editors

Blood Journals Studio

Poster Session I - Viewing

Events

Your New Superpower: Uncertainty Comfort (for in-person participants)

ASH Wellness Studio

Believing Beyond Burnout (for in-person participants)

ASH Wellness Studio

A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs With Leukemia and Lymphoma

Education Program

ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease

Education Program

AML M&Ms: How to Integrate Mutations and MRD Data

Education Program

Ineffective Erythropoiesis: Insights Into Molecular Mechanisms and Disease Pathophysiology

Scientific Program

Moving the Needle in Hodgkin Lymphoma

Education Program

Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation

Education Program

Optimizing Non-Curative Therapies for Sickle Cell Disease

Education Program

Proteo-Genomics to Better Study Multiple Myeloma Biology and Evolution

Scientific Program

The Expanding Landscape of Treatment for ITP

Education Program

Understanding the Impact of Donor and Recipient Metabolic Variability on Blood Transfusion Outcomes

Scientific Program

102. Iron Homeostasis and Biology: New Insights into Iron-related Proteins in Erythropoiesis and Inflammation

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombotic Risk: The Genes We're Born with and Mutations We Acquire

Oral and Poster Abstracts

401. Blood Transfusion: Advancements in Transfusion Science

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Epigenetic and Metabolic Control of Hematopoiesis

Oral and Poster Abstracts

508. Bone Marrow Failure: Acquired: Biological Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Cellular Mechanisms and Therapeutic Strategies

Oral and Poster Abstracts

603. Lymphoid Oncogenesis: Basic: Molecular Insights into Lymphomas and CLL

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Determinants of Venetoclax Resistance and Response

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Multi-omic Applications for Disease Evolution and Response to Therapy

Oral and Poster Abstracts

628. Aggressive Lymphomas: Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas

Oral and Poster Abstracts

641. Chronic Lymphocytic Leukemia: Basic and Translational: Therapeutic Vulnerabilities, Signaling, and Microenvironment

Oral and Poster Abstracts

653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma?

Oral and Poster Abstracts

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and Delivery Strategies

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: CAR-T Cell Therapies for Lymphomas and ALL: New Strategies and Toxicities

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Predicting and Treating Acute and Chronic GVHD

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: New Approaches to Predicting Patient Outcomes in Hematologic Malignancies

Oral and Poster Abstracts

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: 'In with the Old, In with the New': Outcomes of Conventional and Novel Therapeutic Paradigms in Aggressive Lymphoid Malignancies

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Identifying Problems and Providing Solutions to Delivering Myeloid Malignancy Care

Oral and Poster Abstracts

ASH Clinical Practice Guidelines on Pediatric Venous Thromboembolism (VTE)

Special-Interest Sessions

Ensuring Equitable Access to Quality Care for Undocumented Immigrants and Mixed-Status Families

Health Equity Studio

Live Music and Outdoor Lunch Seating (for in-person participants)

Events

Open Time for Lunch

Events

Exhibits Open

Events

Fix Your Seat (for in-person participants)

ASH Wellness Studio

ASH Poster Walk on Hemostasis and Thrombosis: from Basic Concepts to Clinical Applications Hosted by Blood Vessels, Thrombosis & Hemostasis (For In-person Participants)

ASH Poster Walks

Blood Presents: How to Get Published in a Peer-Reviewed Journal

Special-Interest Sessions

Career Development Lunch

Trainee Activities and Services

Grassroots Network Lunch

Special-Interest Sessions

Smarter Phone Use (for in-person participants)

ASH Wellness Studio

A New Treatment Strategy in cGVHD

Product Theaters

Beyond the Data: Long-Term Efficacy & Safety Integrated Analyses and a Patient's Journey with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Product Theaters

CAR T Cell Therapy for Second-line (2L) LBCL

Product Theaters

Choosing a Different Approach: Clinical and Nonclinical Factors for Adults with PNH on FABHALTA

Product Theaters

Getting Started and Transitioning to Outpatient Care for Patients With Relapsed or Refractory Multiple Myeloma

Product Theaters

Learn about an alternative treatment for certain B-cell malignancies. This program is sponsored by Lilly USA, LLC.

Product Theaters

Learn About Time Off Treatment with a BCL-2 Inhibitor-based Regimen for CLL/SLL

Product Theaters

Wellbeing Strategies for High Performance (for in-person participants)

ASH Wellness Studio

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease

Oral and Poster Abstracts

322. Hemophilia A and B: Clinical and Epidemiological: Beyond Efficacy of Hemostatic Agents in Hemophilia: Exploring Pharmacokinetics, Dosing Regimens, and Special Populations

Oral and Poster Abstracts

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Humoral Coagulation Factors: Venous Thrombosis and Beyond

Oral and Poster Abstracts

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: A Brave New World: Novel Tools, Targets and Treatments in TTP

Oral and Poster Abstracts

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations in Mobilization, Collection, and Manufacturing for Cellular Therapies

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Novel Therapeutic Strategies for Hematologic Disorders: From Mechanistic to Preclinical Studies

Oral and Poster Abstracts

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Optimizing Classical Hematology Care

Oral and Poster Abstracts

2024 Ham-Wasserman Lecture

Marquee Sessions

Invivoscribe – Partnering with Pharma to Streamline Oncological Clinical Development

Company Showcases

Using multi-cancer early detection testing to screen for cancers that lack recommended screenings

Company Showcases

Coffee Break in the Exhibit Hall (for in-person participants)

Events

Global Hematology Collaboration: Advancing Diversity and Leadership in Clinical Research

Health Equity Studio

Meet the Blood Editors

Blood Journals Studio

Tools for Success in Early Medical Practice (for in-person participants)

ASH Wellness Studio

Practical Approaches to Combating Burnout (for in-person participants)

ASH Wellness Studio

10x Genomics Company Showcase

Company Showcases

Fresh, Fit and Fast: Pioneering the Future of Cell Therapy through Decentralized Manufacturing

Company Showcases

Beyond TTP: “Atypical” TMAs for the Hematologist

Education Program

Chasing Zebras: Navigating Rare Myeloid Neoplasms

Education Program

Hematologic Challenges at the End-of-Life

Education Program

Hematologic Management of the Patient with Heavy Menstrual Bleeding

Education Program

Host Factors Driving Anti-Leukemia Immunotherapy Outcomes

Scientific Program

Integrating New Therapies into the Management of Classical Heme Disorders

Education Program

Ironing Out the Wrinkles: Managing Iron Overload in Different Clinical Scenarios

Education Program

Newly Diagnosed Multiple Myeloma: Many Choices and More Questions

Education Program

101. Red Cells and Erythropoiesis, Excluding Iron: Effects of Inflammation on Erythropoiesis and the Niche

Oral and Poster Abstracts

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Identification of New Molecular Targets to Modulate Sickle Cell Disease

Oral and Poster Abstracts

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Therapeutic Advances in Sickle Cell Disease

Oral and Poster Abstracts

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets and Endothelium in Thrombotic Disorders

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging, and Inflammation: Mechanisms of Hematopoietic Aging and Inflammation

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Disease Modeling and Molecular Mechanisms

Oral and Poster Abstracts

603. Lymphoid Oncogenesis: Basic: Molecular Insights into Acute Lymphoblastic Leukemias

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel Approaches to Targeting Epigenetics, Apoptosis and Immune Effectors in Myeloid Malignancies

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin Inhibitors in AML

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: Impact of Molecularly-Targeted Agents in AML

Oral and Poster Abstracts

619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Measurable Residual Disease in AML in 2024 and Beyond

Oral and Poster Abstracts

621. Lymphomas: Translational – Molecular and Genetic: Molecular Profiling and Targets in Aggressive Lymphomas

Oral and Poster Abstracts

623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Therapies for Mantle Cell Lymphoma

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Personalized and Molecular Approaches in Myeloproliferative Neoplasms: Risk Stratification and Therapeutic Implications

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes

Oral and Poster Abstracts

653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: GVHD, Mucosal Immunology and the Microbiome

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Adult Patients

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: The Multimodal Future: AI Approaches to Drug Development, Classification and Outcomes

Oral and Poster Abstracts

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: It's All About the Money!

Oral and Poster Abstracts

907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple Myeloma

Oral and Poster Abstracts

Distinguished Abstract Achievement Award Ceremony

Blood Journals Studio

Symposium on Quality: Treating Fairly - The Role of Quality Improvement in Combating Health Care Disparities

Special-Interest Sessions

The ALPHA3 Trial: Harnessing the Potential of Combining Next-Generation “Off-the-Shelf” Investigational CAR T Product with Advanced MRD Testing to Improve Outcomes in First Line LBCL

Clinical Trial Showcases

The spatial organization of surface proteins of single cells in myelodysplastic syndrome for diagnostics and drug target discovery by Molecular Pixelation (MPX)

Company Showcases

Achieving Equity and Inclusion in Clinical Trial Enrollment: Challenges and Opportunities

Health Equity Studio

Coffee Break in the Exhibit Hall (for in-person participants)

Events

Hemato-Logic: How to Share Your Cases with the ASH Image Bank and Blood Work

Blood Journals Studio

The Performance Paradox (for in-person participants)

ASH Wellness Studio

The Anxious Achieving Brain (for in-person participants)

ASH Wellness Studio

A New Era in Research: Pragmatic Prospective Real-World Studies

Company Showcases

Handling Bad News: How to Best Manage TP53 Myeloid Disease

Education Program

HIT-and-Run: Challenges in Diagnosis and Management of Heparin-Induced Thrombocytopenia

Education Program

Interface of Complement and Coagulation

Scientific Symposia

Monoclonal Gammopathies: When the Clone Is More Than a Positive Laboratory Finding

Education Program

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Tools and Biomarkers for Improving Sickle Cell Disease Treatments

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis in Pregnancy and Childhood

Oral and Poster Abstracts

508. Bone Marrow Failure: Acquired: Emerging Data in the Treatment of Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Oral and Poster Abstracts

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Clinical Trials in Pediatric and Young Adult Patients

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Determinants of Outcomes In ALL

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Treatments and Outcomes in AML in Specific Age Groups, and in Blastic Plasmacytoid Dendritic Cell Neoplasms

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Functional Genomics in Prognosis and Novel Therapies

Oral and Poster Abstracts

622. Lymphomas: Translational – Non-Genetic: Novel Immune Evasion Strategies in B Cell Lymphomas

Oral and Poster Abstracts

623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Novel Treatment Strategies and New Data on Old Standards for Follicular Lymphoma

Oral and Poster Abstracts

636. Myelodysplastic Syndromes: Basic and Translational: Disease Mechanisms and Therapeutic Vulnerabilities in Molecular Genetic Subtypes of MDS

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Understanding and Improving TCE and CAR-T Cell Therapies for Plasma Cell Disorders

Oral and Poster Abstracts

653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Myeloid Biology and CAR-T Cells

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Monitoring, Understanding and Optimizing GVHD Interventions

Oral and Poster Abstracts

902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Brighter Tomorrow - Improving Safety of Treatments

Oral and Poster Abstracts

904. Outcomes Research: Hemoglobinopathies: Non-Malignant Conditions: Determinants of Health Equity Across the Spectrum

Oral and Poster Abstracts

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Learning from the Real World: Predictors of Outcomes in Understudied Lymphomas and Underrepresented Populations

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Patient Reported Outcomes and their Association with Clinical Outcomes in Patients with Myeloid Malignancies

Oral and Poster Abstracts

Artificial Intelligence in Hematology: From Generative AI to Ethics and Applications

Special-Interest Sessions

ASH Research Collaborative Multiple Myeloma Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation

Special-Interest Sessions

JOINT SESSION: Molecular Characterization of Lymphomas in Children, Adolescents, and Young Adults

Scientific Program

JOINT SESSION: Newly Described Functions in the Vascular Space

Scientific Program

JOINT SESSION: The Fuel & Physiology of Regeneration

Scientific Program

Poster Session I - Presentations (for in-person participants)

Events

Welcome Reception in the Poster Hall (for in-person participants)

Events

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I

Oral and Poster Abstracts

102. Iron Homeostasis and Biology: Poster I

Oral and Poster Abstracts

112. Thalassemia and Globin Gene Regulation: Poster I

Oral and Poster Abstracts

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I

Oral and Poster Abstracts

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

201. Granulocytes, Monocytes, and Macrophages: Poster I

Oral and Poster Abstracts

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I

Oral and Poster Abstracts

301. Platelets and Megakaryocytes: Basic and Translational: Poster I

Oral and Poster Abstracts

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

321. Coagulation and Fibrinolysis: Basic and Translational: Poster I

Oral and Poster Abstracts

322. Hemophilia A and B: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster I

Oral and Poster Abstracts

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

401. Blood Transfusion: Poster I

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I

Oral and Poster Abstracts

506. Bone Marrow Microenvironment: Poster I

Oral and Poster Abstracts

508. Bone Marrow Failure: Acquired: Poster I

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Poster I

Oral and Poster Abstracts

603. Lymphoid Oncogenesis: Basic: Poster I

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I

Oral and Poster Abstracts

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster I

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I

Oral and Poster Abstracts

619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster I

Oral and Poster Abstracts

621. Lymphomas: Translational – Molecular and Genetic: Poster I

Oral and Poster Abstracts

622. Lymphomas: Translational – Non-Genetic: Poster I

Oral and Poster Abstracts

623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

626. Aggressive Lymphomas: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

627. Aggressive Lymphomas: Pharmacologic Therapies: Poster I

Oral and Poster Abstracts

628. Aggressive Lymphomas: Cellular Therapies: Poster I

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

636. Myelodysplastic Syndromes: Basic and Translational: Poster I

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I

Oral and Poster Abstracts

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

654. Multiple Myeloma: Pharmacologic Therapies: Poster I

Oral and Poster Abstracts

655. Multiple Myeloma: Cellular Therapies: Poster I

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: Poster I

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Oral and Poster Abstracts

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I

Oral and Poster Abstracts

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I

Oral and Poster Abstracts

801. Gene Therapies: Poster I

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Poster I

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I

Oral and Poster Abstracts

900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I

Oral and Poster Abstracts

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I

Oral and Poster Abstracts

902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I

Oral and Poster Abstracts

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster I

Oral and Poster Abstracts

904. Outcomes Research: Hemoglobinopathies: Poster I

Oral and Poster Abstracts

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I

Oral and Poster Abstracts

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I

Oral and Poster Abstracts

907. Outcomes Research: Plasma Cell Disorders: Poster I

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Poster I

Oral and Poster Abstracts

909. Education, Communication, and Workforce: Poster I

Oral and Poster Abstracts

TiPs 1 Poster Session 1 (14 abstracts)

Oral and Poster Abstracts

TiPs 2 Poster Session 1 (55 abstracts)

Oral and Poster Abstracts

TiPs 3 Poster Session 1 (35 abstracts)

Oral and Poster Abstracts

Hematology Inclusion Pathway (HIP) Oral Presentations - Classical Hematology

Special-Interest Sessions

Hematology Inclusion Pathway (HIP) Oral Presentations - Health Services Outcomes

Special-Interest Sessions

Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology

Special-Interest Sessions

Hematology Inclusion Pathway (HIP) Networking Reception

Special-Interest Sessions

ASH Foundation Run/Walk

Events

Registration at the Convention Center (for in-person participants)

Events

Learn, Engage, and Relax in ASH Central (for in-person participants)

Events

Medical Educators Symposium

Special-Interest Sessions

ASH Poster Walk on Deciphering the Hematopoietic Stem Cell Niche: From Normal Function to Malignancy Hosted by Blood Neoplasia (For In-person Participants)

ASH Poster Walks

Coffee and Collaboration in ASH Central (for in-person participants)

Events

How I Treat: A Personal Journey with Castleman Disease (ticketed session for in-person participants)

How I Treat

How I Treat: Acute Myeloid Leukemia with Targetable Mutations (ticketed session for in-person participants)

How I Treat

How I Treat: Adult Outpatient CAR T Therapy (ticketed session for in-person participants)

How I Treat

How I Treat: Newly Diagnosed Multiple Myeloma (ticketed session for in-person participants)

How I Treat

How I Treat: Sickle Cell Disease in Africa (ticketed session for in-person participants)

How I Treat

KMT2A rearrangements in acute leukemia

Industry Theaters

Meet the Scientist: Mechanisms of Drug Resistance in Acute Myeloid Leukemia (Ticketed session for in-person participants)

Meet the Scientist

Meet the Scientist: Microenvironment Regulation of Hematopoietic Stem Cells (Ticketed session for in-person participants)

Meet the Scientist

Meet the Scientist: Pluripotent Stem Cell-Based Modeling of Hematologic Malignancies (Ticketed session for in-person participants)

Meet the Scientist

Meet the Scientist: What Does the Future Hold for Management of Hemophilia? (Ticketed session for in-person participants)

Meet the Scientist

Options When a Matched Allogeneic-HCT Source is Not Available

Product Theaters

Redefining Frontline Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Product Theaters

The Potential Impact of 24-Hour NGS Results on Myeloid and Lymphoid Malignancy Sample Characterization and Research

Industry Theaters

The Science Behind HYMPAVZI (Marstacimab-hncq): Introducing an Innovative Treatment Option from Pfizer

Product Theaters

Transforming aTTP/iTTP Treatment and Management

Product Theaters

Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 3L+ FL

Product Theaters

Coffee Break in the Poster Hall (for in-person participants)

Events

Combating Structural Racism for Native Hawaiian and Other Pacific Islanders in Health Data

Health Equity Studio

Meet the Blood Neoplasia Editors

Blood Journals Studio

Poster Session II - Viewing

Events

Reframing "the Grind" (for in-person participants)

ASH Wellness Studio

The Appreciation Prescription (for in-person participants)

ASH Wellness Studio

Interrogating the Impact of the Intestinal Microbiome on Transplant and Cellular Therapies

Scientific Symposia

Metabolic Deregulation in Hematopoietic Neoplasia: Tumor, The Environment, and Therapies.

Scientific Program

MPN Practice Pearls: Profiling, Pegylated IFN and Pregnancy

Education Program

Overcoming Post-transplant Relapse: How to Win the Battle Royale

Education Program

112. Thalassemia and Globin Gene Regulation: We're Going to Catch a Big One: Towards Targeted Therapies in Thalassemia

Oral and Poster Abstracts

201. Granulocytes, Monocytes, and Macrophages: Uncovering Pathways Impacting Inflammation, Myeloid Proliferation and Severe Congenital Neutropenia

Oral and Poster Abstracts

301. Platelets and Megakaryocytes: Basic and Translational: Megakarocyte and Platelet Biology: From Formation to Function

Oral and Poster Abstracts

321. Coagulation and Fibrinolysis: Basic and Translational. A Coagulation Grab Bag

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Metabolism, Differentiation and Inflammation

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Clinical and Translational Insights from Patients and Models

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions-Impact on AML Outcomes

Oral and Poster Abstracts

621. Lymphomas: Translational – Molecular and Genetic: Single-cell and Spatial Analyses in Aggressive and T Cell Lymphomas

Oral and Poster Abstracts

624. Hodgkin Lymphomas: Clinical and Epidemiological: Potentially Practice-Changing Trials in Hodgkin Lymphoma

Oral and Poster Abstracts

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas

Oral and Poster Abstracts

626. Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Novel Molecules in Clinical Practice

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents

Oral and Poster Abstracts

653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice

Oral and Poster Abstracts

654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation

Oral and Poster Abstracts

801. Gene Therapies: Gene Editing and Replacement Therapies for Hemoglobinopathies: From Bench to Bedside

Oral and Poster Abstracts

900. Health Services and Quality Improvement: Hemoglobinopathies: Navigating and Optimizing Healthcare Systems

Oral and Poster Abstracts

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T Cell Therapy in Action: Real-World Outcomes in Lymphoma

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Social and Economic Disparities in Treatments, Outcomes and Financial Toxicity

Oral and Poster Abstracts

ASH Clinical Practice Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults

Special-Interest Sessions

Health Equity Symposium: Race, Structural Racism and the Social Determinants of Health in Hematology

Special-Interest Sessions

Sickle Cell Disease Centers Session

Special-Interest Sessions

JOINT SESSION: Emerging Therapeutic Strategies Targeting Epigenetic, Transcriptomic, and Metabolic Mechanisms

Scientific Program

JOINT SESSION: Therapeutic Gene Editing of Stem Cells in Classical and Malignant Hematology

Scientific Program

Exhibits Open

Events

Strengthening the Provider-Patient Relationship: A Guide to Building Trust

Health Equity Studio

Complimentary Light Lunch in the Exhibit Hall (for in-person participants)

Events

LGBTQIA+ Community Networking Brunch (for in-person participants)

Special-Interest Sessions

Live Music and Outdoor Lunch Seating (for in-person participants)

Events

Walking Wonders (for in-person participants)

ASH Wellness Studio

ASH Poster Walk on What's New in Complement-Related Diseases? Hosted by Blood Red Cells & Iron (For In-person Participants)

ASH Poster Walks

Blood Advances Presents: How to Peer Review a Scientific Paper

Special-Interest Sessions

Trainee Didactic Session: Creating a Laboratory and Clinical Research Program from Scratch

Trainee Activities and Services

Trainee Didactic Session: Time Management in Clinical and Research: There are only 24 hours in a day or Everyone Needs a System

Trainee Activities and Services

ASH Clinicians in Practice (ACIP) Lunch - The Role of Artificial Intelligence in Hematology Practice: The Good, the Bad, and the Ugly

Special-Interest Sessions

How to Stand (for in-person participants)

ASH Wellness Studio

Addressing Critical Unmet Needs With Newly Diagnosed Ph+CML-CP

Product Theaters

A First-Line Treatment Option for Adults with Symptomatic Anemia Due To Lower-Risk MDS

Product Theaters

Discover Gene Therapy as a Treatment Option for Hemophilia B

Product Theaters

Discover the exciting details about a BCMA Bispecific for 4L+ RRMM

Product Theaters

Exploring CLL and MCL: Disease Overview, Latest Treatment Options and Unmet Needs

Industry Theaters

Health Equity Rounds Lunch

Special-Interest Sessions

Innovations in Hemophilia Research: Fitusiran, An Investigational Rebalancing Agent for the Treatment of Hemophilia

Industry Theaters

The Performance Paradox (for in-person participants)

ASH Wellness Studio

101. Red Cells and Erythropoiesis, Excluding Iron: Regulation of Erythropoiesis

Oral and Poster Abstracts

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Improving Outcomes in Sickle Cell Disease Around the World

Oral and Poster Abstracts

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Big Data and Basic Science

Oral and Poster Abstracts

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Treatments and Outcomes

Oral and Poster Abstracts

506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Normal Hematopoiesis

Oral and Poster Abstracts

624. Hodgkin Lymphomas: Clinical and Epidemiological: Optimization of Therapy

Oral and Poster Abstracts

626. Aggressive Lymphomas: Clinical and Epidemiological: Challenging Subtypes of Aggressive Lymphomas

Oral and Poster Abstracts

627. Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Mutations, Prognosis and MRD in CLL

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Resistance and Response to Anti-Myeloma Therapies

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Long-term Outcomes Including in Bone Marrow Failure and Rare Diseases

Oral and Poster Abstracts

900. Health Services and Quality Improvement: Hemoglobinopathies: Empowering Choices: Navigating Shared Decision-Making for Patient-Centric Care

Oral and Poster Abstracts

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Driving the CARs Home: Real-World Safety and Outcomes of CAR-T Cell Therapies

Oral and Poster Abstracts

909. Education, Communication, and Workforce: Bridging the Gap: Enhancing Communication and Education for Hematologists and our Patients

Oral and Poster Abstracts

ASH-EHA Joint Symposium

Marquee Sessions

Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, and the Outstanding Service Award

Marquee Sessions

Global Hematology Collaboration: Advancing Diversity and Leadership in Clinical Research

Health Equity Studio

Simulcast of Announcement of Awards and Plenary Scientific Session (for in-person participants)

Special-Interest Sessions

Simulcast of Announcement of Awards and Plenary Scientific Session (for in-person participants)

Special-Interest Sessions

Simulcast of Announcement of Awards and Plenary Scientific Session (for in-person participants)

Special-Interest Sessions

Simulcast of Announcement of Awards and Plenary Scientific Session (for in-person participants)

Special-Interest Sessions

Plenary Scientific Session

Marquee Sessions

Achieving Equity and Inclusion in Clinical Trial Enrollment: Challenges and Opportunities

Health Equity Studio

Coffee Break in the Exhibit Hall (for in-person participants)

Events

Meet the Blood Advances Editors

Blood Journals Studio

Foundations of Mindfulness (for in-person participants)

ASH Wellness Studio

Cultivating Compassion (for in-person participants)

ASH Wellness Studio

Biology Underlying Disparities in Lymphoid Malignancies

Spotlight Sessions

Cellular Heterogeneity and Relationship to Clinical Outcomes

Scientific Symposia

Challenges in Cancer-Associated Thrombosis

Education Program

Curative Therapies for Sickle Cell Disease: Option for Some but Not Quite All

Spotlight Sessions

Follicular Lymphoma: Playing the Long Game

Education Program

Inflammation as a Regulator of Hematopoietic Homeostasis in Disease and Clonal Selection

Spotlight Sessions

Newly Discovered Functions of Megakaryocytes and Platelets

Scientific Symposia

Paradigm Shifts in Hemostasis: From Mechanisms to Therapies and Back

Scientific Program

Race and Ancestry in Precision Medicine

Special-Interest Sessions

The Clone Wars: Myeloid Neoplasia Risk in Clonal Hematopoiesis

Spotlight Sessions

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Attenuating Sickle Cell Disease Complications – Lessons from Pre-clinical Models

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Models and Mechanisms in AML Biology

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Understanding and Exploiting Molecular Therapeutic Targets in ALL

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Deciphering the Mechanisms Underlying Prognosis

Oral and Poster Abstracts

622. Lymphomas: Translational – Non-Genetic: Demystifying the Complexity of the Lymphoma Tumor Microenvironment and Immune Responses

Oral and Poster Abstracts

626. Aggressive Lymphomas: Clinical and Epidemiological: New Prognostic Tools and Treatment Outcomes in Diffuse Large B Cell Lymphoma

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment and Prognostication of MDS

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Microenvironment and Immunity in Myeloma

Oral and Poster Abstracts

654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: B Cell-directed CAR T Cell Therapies for ALL and for Autoimmunity

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Risk Adapted Approaches to Reduce Transplant Related Toxicities

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA

Oral and Poster Abstracts

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Practice-Changing Outcomes Research for Patients with Thrombosis

Oral and Poster Abstracts

907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting Outcomes

Oral and Poster Abstracts

ASH Clinical Practice Guidelines on Amyloidosis

Special-Interest Sessions

Symposium for Mid-Career Hematologists

Special-Interest Sessions

Systems-Based Hematology Education and Networking Session: Anticoagulation Stewardship and AI-Assisted Management

Special-Interest Sessions

Poster Hall Reception (for in-person participants)

Events

Poster Session II - Presentations (for in-person participants)

Events

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II

Oral and Poster Abstracts

102. Iron Homeostasis and Biology: Poster II

Oral and Poster Abstracts

112. Thalassemia and Globin Gene Regulation: Poster II

Oral and Poster Abstracts

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II

Oral and Poster Abstracts

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

201. Granulocytes, Monocytes, and Macrophages: Poster II

Oral and Poster Abstracts

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II

Oral and Poster Abstracts

301. Platelets and Megakaryocytes: Basic and Translational: Poster II

Oral and Poster Abstracts

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

321. Coagulation and Fibrinolysis: Basic and Translational: Poster II

Oral and Poster Abstracts

322. Hemophilia A and B: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster II

Oral and Poster Abstracts

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

401. Blood Transfusion: Poster II

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II

Oral and Poster Abstracts

506. Bone Marrow Microenvironment: Poster II

Oral and Poster Abstracts

508. Bone Marrow Failure: Acquired: Poster II

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Poster II

Oral and Poster Abstracts

603. Lymphoid Oncogenesis: Basic: Poster II

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II

Oral and Poster Abstracts

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster II

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II

Oral and Poster Abstracts

619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster II

Oral and Poster Abstracts

621. Lymphomas: Translational – Molecular and Genetic: Poster II

Oral and Poster Abstracts

622. Lymphomas: Translational – Non-Genetic: Poster II

Oral and Poster Abstracts

623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

626. Aggressive Lymphomas: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

627. Aggressive Lymphomas: Pharmacologic Therapies: Poster II

Oral and Poster Abstracts

628. Aggressive Lymphomas: Cellular Therapies: Poster II

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

636. Myelodysplastic Syndromes: Basic and Translational: Poster II

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II

Oral and Poster Abstracts

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

653. Multiple Myeloma: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

654. Multiple Myeloma: Pharmacologic Therapies: Poster II

Oral and Poster Abstracts

655. Multiple Myeloma: Cellular Therapies: Poster II

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: Poster II

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Oral and Poster Abstracts

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster II

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II

Oral and Poster Abstracts

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II

Oral and Poster Abstracts

801. Gene Therapies: Poster II

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Poster II

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II

Oral and Poster Abstracts

900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II

Oral and Poster Abstracts

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II

Oral and Poster Abstracts

902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II

Oral and Poster Abstracts

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II

Oral and Poster Abstracts

904. Outcomes Research: Hemoglobinopathies: Poster II

Oral and Poster Abstracts

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II

Oral and Poster Abstracts

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II

Oral and Poster Abstracts

907. Outcomes Research: Plasma Cell Disorders: Poster II

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Poster II

Oral and Poster Abstracts

909. Education, Communication, and Workforce: Poster II

Oral and Poster Abstracts

ASH Yoga (for in-person participants)

Events

Registration at the Convention Center (for in-person participants)

Events

Learn, Engage, and Relax in ASH Central (for in-person participants)

Events

ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights Hosted by Blood Immunology & Cellular Therapy (For In-person Participants)

ASH Poster Walks

A first-in-class treatment for RRMM patients

Product Theaters

Coffee and Collaboration in ASH Central (for in-person participants)

Events

Combating Structural Racism for Native Hawaiian and Other Pacific Islanders in Health Data

Health Equity Studio

Meet the Blood Editors

Blood Journals Studio

E. Donnall Thomas Lecture and Prize

Marquee Sessions

Poster Session III - Viewing

Events

Best Practices for Peer Review: ASH Clinical News interviews the Blood Advances Editors

Blood Journals Studio

Coffee Break in the Exhibit Hall (for in-person participants)

Events

Ensuring Equitable Access to Quality Care for Undocumented Immigrants and Mixed-Status Families

Health Equity Studio

Exhibits Open

Events

Vitamin V: Visualize to Revitalize (for in-person participants)

ASH Wellness Studio

The Encouragement Elixir (for in-person participants)

ASH Wellness Studio

Anticoagulation SOS: Navigating Monitoring Conundrums

Education Program

A Shifting Landscape: Treatment of MCL

Education Program

Challenges and Opportunities of Sickle Cell Care in Africa

Education Program

It's a Different World: CLL 2024

Education Program

Leveraging Single Cell Multi-Omics to Understand Mechanisms of Myeloid Lineage Expansion in Aging and Disease.

Scientific Program

Making a Match: Optimal Donor HLA and Beyond

Spotlight Sessions

Phylogenetic Reconstruction of Hematopoiesis

Spotlight Sessions

Smoldering Myeloma: A Case for Early Intervention?

Spotlight Sessions

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Evidence in ITP

Oral and Poster Abstracts

322. Hemophilia A and B: Clinical and Epidemiological: Impact of Novel Therapies on Outcomes, Including Long-Term

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Resistance to Standard and Novel Therapies

Oral and Poster Abstracts

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Look into the Crystal B-ALL: Genetic, Phenotypic and Dynamic Outcome Predictors in Lymphoblastic Leukemia

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML

Oral and Poster Abstracts

621. Lymphomas: Translational – Molecular and Genetic: Single-cell and Spatial Analyses in Indolent Lymphomas

Oral and Poster Abstracts

623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent Lymphomas

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stem Cell Biology in Myeloproliferative Syndromes

Oral and Poster Abstracts

641. Chronic Lymphocytic Leukemia: Basic and Translational: CLL and Richter Transformation: Functional Genomics and Molecular Mechanisms

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in Myeloma

Oral and Poster Abstracts

654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant

Oral and Poster Abstracts

902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow - Improving Access to Blood Cancer Treatments and Trials

Oral and Poster Abstracts

903. Health Services and Quality Improvement: Myeloid Malignancies: Innovative Approaches to Improve Quality of Care, Affordability, and Outcomes

Oral and Poster Abstracts

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Innovative Approaches to Improve Care for Understudied Non-Malignant Hematologic Diseases

Oral and Poster Abstracts

ASH-FDA Joint Symposium I

Special-Interest Sessions

Early Faculty Career Development Session

Special-Interest Sessions

Advocating for Language Justice in Hematology

Health Equity Studio

The ABCs of Publishing for Authors: The Hematologist interviews the Blood Editors

Blood Journals Studio

DEI Community Networking Lunch (for in-person participants)

Special-Interest Sessions

Complimentary Light Lunch in the Exhibit Hall (for in-person participants)

Events

Live Music and Outdoor Lunch Seating (for in-person participants)

Events

The Life-Changing Effect of Meditation (for in-person participants)

ASH Wellness Studio

A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS

Product Theaters

Energizing Red Blood Cells: The Latest Data in Thalassemia

Industry Theaters

Trainee Didactic Session: Building, Nurturing, and Sustaining a Research Program

Trainee Activities and Services

Trainee Didactic Session: Setting up a Health Services and Outcomes Research Program

Trainee Activities and Services

What's Next for Patients with 2L+ Relapsed or Refractory Multiple Myeloma?

Product Theaters

Whistle While You Work (for in-person participants)

ASH Wellness Studio

ASH Poster Walk on Improving Access to Cell and Gene Therapies Hosted by Blood Global Hematology (For In-person Participants)

ASH Poster Walks

H2O-M-G! (for in-person participants)

ASH Wellness Studio

Strengthening the Provider-Patient Relationship: A Guide to Building Trust

Health Equity Studio

Ernest Beutler Lecture and Prize

Marquee Sessions

Coffee Break in the Poster Hall (for in-person participants)

Events

Adult ALL Advancements: Optimizing Cure in 2024

Education Program

Fulfilling the Promise: Pluripotent Stem Cells as Models for Human Blood Development and Disease

Spotlight Sessions

Gene Therapy and Hemophilia A: What Is the Future of Curative Therapy in the Age of Emicizumab?

Spotlight Sessions

Iron at the Crossroads Between Erythropoiesis and Megakaryopoiesis

Spotlight Sessions

Sex Hormones, Contraceptives, and Thrombotic Risk: Where Are We Now?

Education Program

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: The Effects of Sickle Cell Disease on Organ Function

Oral and Poster Abstracts

201. Granulocytes, Monocytes, and Macrophages: From Inflammation to Hemophagocytic Lymphohistiocytosis

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis: Models, Risk Factors, and Outcomes

Oral and Poster Abstracts

506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Disease

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: New Targets and Drugs

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Mechanisms of Therapy Resistance in Lymphoma

Oral and Poster Abstracts

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Treatment of BCR:ABL+ and T Cell Diseases

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Genetic Markers and Outcomes in AML

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Refining Diagnostic Risk Assessment

Oral and Poster Abstracts

621. Lymphomas: Translational – Molecular and Genetic: Molecular Profiling and Prognostic Biomarkers in Hodgkin and Non-Hodgkin Lymphomas

Oral and Poster Abstracts

623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom's Macroglobulinemia and Hairy Cell Leukemia

Oral and Poster Abstracts

627. Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: New Insights into The Biology of Myeloproliferative Syndromes

Oral and Poster Abstracts

636. Myelodysplastic Syndromes: Basic and Translational: Novel Mechanisms of Aberrant Hematopoiesis and Immune Evasion in MDS

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life

Oral and Poster Abstracts

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL Amyloidosis

Oral and Poster Abstracts

653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early Relapse

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: GVHD, GVL and Alloimmunity

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Acute and Late Toxicities Following CAR-T Cell Therapy

Oral and Poster Abstracts

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Enhancing NK Cell Therapeutics

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Exploring Biologic Mechanisms of Relapse and Survival

Oral and Poster Abstracts

907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies

Oral and Poster Abstracts

ASH Quality Improvement Champions

Special-Interest Sessions

Addressing Unmet Needs in T Cell Lymphomas

Education Program

Adult CAR-T Outcomes: Beyond the Acronyms (OS, PFS, CRS, ICANS)

Education Program

Crosstalk Between Iron Homeostasis and Metabolism

Scientific Program

Placing the Brakes on Accelerated Aging

Scientific Symposia

Vascular Anomalies, Vascular Malformations, and the Role of the Hematologist

Education Program

101. Red Cells and Erythropoiesis, Excluding Iron: Erythropoiesis in Disease

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging, and Inflammation: Causes and Consequences

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: CRISPR Screens and Other New Approaches to Understanding Myeloid Neoplasia

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma

Oral and Poster Abstracts

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Stratification and CAR-T Therapies

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: Optimizing Regimens in Children/Young Adults and Around the World

Oral and Poster Abstracts

622. Lymphomas: Translational – Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies

Oral and Poster Abstracts

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move the Needle in T Cell Lymphomas?

Oral and Poster Abstracts

627. Aggressive Lymphomas: Pharmacologic Therapies: Chemotherapy-free Combinations for Relapsed Aggressive Lymphomas

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Alternative Laboratory Predictors of Outcome

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Chronic Myelomonocytic Leukemia

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations

Oral and Poster Abstracts

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM

Oral and Poster Abstracts

654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma

Oral and Poster Abstracts

655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Novel Targets and Therapeutic Approaches for CAR-T Cells

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Avoiding GVHD and Improving Outcomes

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse

Oral and Poster Abstracts

801. Gene Therapies: Gene Therapies for Hemophilia, Cancer and Immunodeficiencies

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Pioneering Tools for Tomorrow's Breakthroughs

Oral and Poster Abstracts

904. Outcomes Research: Hemoglobinopathies: Non-Malignant Conditions: Transforming Care: Insights into Healthcare Utilization, Outcome Measurement, and Treatment Impact in Sickle Cell Disease

Oral and Poster Abstracts

ASH-FDA Joint Symposium II

Special-Interest Sessions

ASH Research Collaborative Data Hub Sickle Cell Disease Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation

Special-Interest Sessions

Special Symposium on the Basic Science of Hemostasis and Thrombosis

Scientific Symposia

ASH Networking Reception for the Hemostasis and Thrombosis Community - Hosted by the Blood Vessels, Thrombosis and Hemostasis Journal

Special-Interest Sessions

Center for Sickle Cell Disease Initiatives: Advancing Progress in Sickle Cell Disease Update and Reception: hosted by ASH and ASH Research Collaborative

Special-Interest Sessions

Poster Hall Reception (for in-person participants)

Events

Poster Session III - Presentations (for in-person participants)

Events

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III

Oral and Poster Abstracts

102. Iron Homeostasis and Biology: Poster III

Oral and Poster Abstracts

112. Thalassemia and Globin Gene Regulation: Poster III

Oral and Poster Abstracts

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III

Oral and Poster Abstracts

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

201. Granulocytes, Monocytes, and Macrophages: Poster III

Oral and Poster Abstracts

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III

Oral and Poster Abstracts

301. Platelets and Megakaryocytes: Basic and Translational: Poster III

Oral and Poster Abstracts

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

321. Coagulation and Fibrinolysis: Basic and Translational: Poster III

Oral and Poster Abstracts

322. Hemophilia A and B: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III

Oral and Poster Abstracts

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

401. Blood Transfusion: Poster III

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III

Oral and Poster Abstracts

506. Bone Marrow Microenvironment: Poster III

Oral and Poster Abstracts

508. Bone Marrow Failure: Acquired: Poster III

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Poster III

Oral and Poster Abstracts

603. Lymphoid Oncogenesis: Basic: Poster III

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III

Oral and Poster Abstracts

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster III

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III

Oral and Poster Abstracts

619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster III

Oral and Poster Abstracts

621. Lymphomas: Translational – Molecular and Genetic: Poster III

Oral and Poster Abstracts

622. Lymphomas: Translational – Non-Genetic: Poster III

Oral and Poster Abstracts

623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

626. Aggressive Lymphomas: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

627. Aggressive Lymphomas: Pharmacologic Therapies: Poster III

Oral and Poster Abstracts

628. Aggressive Lymphomas: Cellular Therapies: Poster III

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

636. Myelodysplastic Syndromes: Basic and Translational: Poster III

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III

Oral and Poster Abstracts

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III

Oral and Poster Abstracts

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

653. Multiple Myeloma: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

654. Multiple Myeloma: Pharmacologic Therapies: Poster III

Oral and Poster Abstracts

655. Multiple Myeloma: Cellular Therapies: Poster III

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: Poster III

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Oral and Poster Abstracts

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster III

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III

Oral and Poster Abstracts

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III

Oral and Poster Abstracts

801. Gene Therapies: Poster III

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Poster III

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III

Oral and Poster Abstracts

900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III

Oral and Poster Abstracts

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III

Oral and Poster Abstracts

902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III

Oral and Poster Abstracts

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III

Oral and Poster Abstracts

904. Outcomes Research: Hemoglobinopathies: Poster III

Oral and Poster Abstracts

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III

Oral and Poster Abstracts

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III

Oral and Poster Abstracts

907. Outcomes Research: Plasma Cell Disorders: Poster III

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Poster III

Oral and Poster Abstracts

909. Education, Communication, and Workforce: Poster III

Oral and Poster Abstracts

Women In Hematology Networking Event (for in-person participants)

Special-Interest Sessions

Registration at the Convention Center (for in-person participants)

Events

Learn, Engage, and Relax in ASH Central (for in-person participants)

Events

Late-Breaking Abstracts Session

Marquee Sessions

Morning Coffee and Tuesday Marquee Sessions (for in-person participants)

Events

Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals

Marquee Sessions

2024 Presidential Symposium

Marquee Sessions

Business Meeting and Ceremonial Passing of the ASH President's Gavel

Marquee Sessions

Best of ASH

Marquee Sessions

Binge-Watch Content on the Virtual Platform

Events

ASH Poster Walk on Hello, World! A Walk Through The Artificial Intelligence Network

ASH Poster Walks

ASH Poster Walk on Health Equity in Hematology

ASH Poster Walks

Binge-Watch Content on the Virtual Platform

Events

Binge-Watch Content on the Virtual Platform

Events

66th ASH Annual Meeting

Wednesday, December 4, 2024

9:00 AM-11:55 PM

Thursday, December 5, 2024

1:00 AM-11:55 PM

5:30 AM-10:00 PM

3:00 PM-7:00 PM

Friday, December 6, 2024

5:30 AM-10:00 PM

7:00 AM-10:00 AM

7:00 AM-6:00 PM

9:00 AM-12:00 PM

11:00 AM-2:00 PM

2:00 PM-5:00 PM

Scientific Workshops

3:00 PM-6:00 PM

7:00 PM-10:00 PM

Saturday, December 7, 2024

7:00 AM-7:45 AM

7:00 AM-6:00 PM

8:00 AM-9:00 AM

9:00 AM-9:30 AM

9:00 AM-7:30 PM

9:05 AM-9:15 AM

9:15 AM-9:25 AM

9:30 AM-10:45 AM

9:30 AM-11:00 AM

11:00 AM-11:30 AM

11:00 AM-12:30 PM

11:00 AM-5:00 PM

11:05 AM-11:15 AM

11:15 AM-12:15 PM

11:20 AM-11:30 AM

11:30 AM-12:30 PM

11:35 AM-11:45 AM

12:00 PM-1:30 PM

12:30 PM-1:30 PM

1:30 PM-1:45 PM

1:30 PM-2:00 PM

1:35 PM-1:45 PM

1:45 PM-1:55 PM

1:45 PM-2:00 PM

2:00 PM-3:15 PM

2:00 PM-3:30 PM

3:30 PM-3:45 PM

3:30 PM-4:00 PM

3:35 PM-3:45 PM

3:45 PM-3:55 PM

3:45 PM-4:00 PM

4:00 PM-5:15 PM

4:00 PM-5:30 PM

4:00 PM-5:35 PM

5:30 PM-7:30 PM

6:00 PM-9:00 PM

8:00 PM-9:00 PM

Sunday, December 8, 2024

7:00 AM-9:00 AM

7:00 AM-5:00 PM

7:00 AM-6:00 PM

7:30 AM-9:30 AM

8:00 AM-9:00 AM

9:00 AM-9:30 AM

9:00 AM-8:00 PM

9:05 AM-9:15 AM

9:15 AM-9:25 AM

9:30 AM-10:45 AM

9:30 AM-11:00 AM

9:30 AM-11:05 AM

10:00 AM-5:00 PM

11:00 AM-11:30 AM

11:00 AM-12:30 PM

11:05 AM-11:15 AM

11:15 AM-12:15 PM

11:15 AM-12:30 PM

11:20 AM-11:30 AM

11:30 AM-12:30 PM

11:35 AM-11:45 AM

12:00 PM-1:30 PM

12:30 PM-1:30 PM

1:30 PM-2:00 PM